Priya Chandran is a core member of the Health Care and Public Sector practices at Boston Consulting Group, and leads the firm’s work on public sector health care systems globally. 

She is a core member of the biopharma team within the Health Care practice, and has worked with various biopharma players on topics including R&D, M&A, large-scale transformations, corporate and therapeutic strategies, market access, and medical and regulatory strategy. 

As Health Care Systems lead, Priya leads a global team which serves governments across the world in strengthening their health care systems. Within the US, Priya and her teams have supported US government health organizations on reforms focused on organizational redesign, data and analytics, process excellence, and quality improvement. 

Prior to joining BCG, Priya was a researcher and project analyst at Ligand Pharmaceuticals in San Diego.

AREAS OF EXPERTISE

  • Leads the firm’s health care systems sector
  • Biopharma corporate strategy and large scale transformations
  • Innovation, access, and affordability
  • PMI and carve-outs
  • R&D and commercial strategies across areas
  • Government health organizational design and process transformations
  • Data and analytics in public and private sector

EDUCATION

  • Integrated BS/MS, Indian Institute of Technology
  • MS, biological chemistry, University of Michigan
  • MBA, honors, University of Chicago

Publications and Videos

Five-Lessons-from-the-Pandemic-for-Health-Care-Systems-rectangle.jpg

Five Lessons from the Pandemic for Health Care Systems

Organizations must build on the momentum from their response to the crisis, delivering better care at lower overall cost and becoming more resilient to future disruptions.
start-reimagining-government-now-rectangle-tcm9-249031.jpg

Start Reimagining Government Now

COVID-19 has massive implications for governments, including increased demand for public services and the need to improve resilience. To adapt, leaders must rethink governments’ roles and processes.
bcg-publication-2.jpg

Moving Medical Affairs to the Pharma Forefront

Straddling the R&D and commercial sides of a typical pharma organization means medical affairs is naturally positioned to play an expanded role along the full pharma value chain. The combination of exploding data from internal and external sources, and a stronger focus on value and outcomes, has reshaped the requirements and expectations for drug development and commercialization businesses.
innovative-solutions-biopharma-1694x950-tcm9-83083.jpg

Innovative Solutions for Biopharma

The biopharmaceutical industry must respond to a health care community that increasingly demands the delivery not just of drugs and devices but of positive health outcomes.
2013-rasing-the-bar-1116x626-tcm9-95637.jpg

Raising the Bar in Biopharma Medical Affairs

“Medical affairs” has become increasingly important as physicans’ medical-information needs have grown and become more complex. Here’s how pharma companies can respond to the challenge.
2013-rethinking-corpphilanthropy-1116x626-tcm9-97348.jpg

Rethinking Corporate Philanthropy

Faced with potential funding cutbacks and the need to do more with less, companies are seeking ways to get a greater return on their social investments.
Deep Expertise, Broad Experience